New Promising Prostate Cancer Drug Profiled

New Promising Prostate Cancer Drug Profiled
A new drug candidate to treat challenging cases of prostate cancer, galeterone (VN/124-1), has provided strong preliminary results in clinical trials, leading the U.S. Food and Drug Administration (FDA) to put it on a fast track for approval. The compound was developed 10 years ago in the laboratories of the University of Maryland School of

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *